Posts by: Iqra Mumal, MSc

Iqra Mumal, MSc

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

May 4, 2020May 4, 2020

GCase Screening in Dried Blood Spots Can Diagnose GD Early in High-risk Groups, Study Says

News

Measuring glucocerebrosidase (GCase) activity in dried blood spots is a reliable and cost-effective method to diagnose Gaucher disease early in individuals with splenomegaly (enlarged spleen) and/or thrombocytopenia (low blood platelet count), ... Read more

November 25, 2019November 25, 2019

Study Finds Peripheral Nerve Damage Not to be Significant Feature of Gaucher Type 3

News

Polyneuropathy — which refers to damage in peripheral nerves — is not a significant feature of Gaucher disease, particularly in people with the type 3 form, according to a ... Read more

November 11, 2019November 11, 2019

Gaucher Patients Want to Be Informed at Diagnosis of Parkinson’s Risk, Study Reports

News

Most people with Gaucher disease (GD) would like to be informed by their health care provider at diagnosis of their risk of developing Parkinson’s disease, a survey among U.S. ... Read more

September 5, 2019

Study Finds Biomarkers That Might Inform Severity of Gaucher Manifestations

News

Levels of the biomarkers cathepsin D, cathepsin S, YKL-40, and progranulin are not accurate enough to measure disease activity in Gaucher disease patients, but might inform the severity of ... Read more

July 11, 2019

Lyso-Gb1 Biomarker May Be Useful for Monitoring Disease Activity in Children, Study Suggests

News

Glucosylsphingosine (lyso-Gb1) seems to be a useful biomarker for monitoring disease activity in children with Gaucher disease, helping physicians determine when enzyme replacement therapy should be initiated, a study ... Read more

June 20, 2019

Non-motor Symptoms Preceding Parkinson’s Onset Prevalent in Gaucher Type 1, Study Finds

News

Non-motor symptoms associated with the eventual development of Parkinson’s disease are prevalent in Gaucher disease type 1 patients — people who already are at a higher risk for the ... Read more

June 3, 2019

MicroRNA Inactivation Fails to Reduce Inflammation, Increase Survival in Zebrafish Models of Gaucher

News

Despite its well-known role in inflammation, the microRNA molecule known as miR-155 does not seem to be a promising target for the treatment of Gaucher disease, as its inactivation ... Read more

September 11, 2018

Sanofi’s Cerezyme Should Be Administered Under Current Guidelines with Potential for Change, Study Says

News

Newly discovered data on the activity of glucocerebrosidase after treatment with Sanofi Genzyme’s Cerezyme (imiglucerase) — an enzyme replacement therapy for Gaucher disease — supports current guidelines for its administration every ... Read more

July 10, 2018

Excess Sphingolipids in Gaucher Disease Plays Important Role in Bone Disease, Study Finds

News

An excess of sphingolipids — a hallmark of Gaucher disease — contributes to an imbalance in bone formation and degradation, leading to the development of bone disease, according to ... Read more

April 19, 2018

Gaucher Disease a Rare Cause of Liver, Spleen Enlargement, Case Report Finds

News

Hepatosplenomegaly — enlargement of the liver and spleen — can develop as a result of Gaucher disease in adults, according to a case report. The case report, “Gaucher disease ... Read more